A sector-exclusive life sciences venture and growth equity fund focused on Asia, particularly China, is currently investing from its latest fund closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round, and while the firm focuses on China they also consider opportunities from USA.

In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based private investment firm is focused on healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm is open to opportunities across North America and is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a global company seeks to make strategic investments into early-stage companies that are aligned with the company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the firm’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent company.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platform technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Canada is exclusively focused on supporting entrepreneurs commercializing advanced materials and advanced material process innovations within four verticals: energy, electronics, health, and sustainability. The firm typically makes initial investments in the $1M-$4M range and up to $8M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. The firm has strategic LP relationships in Asia, Europe, the Middle East, and North America and invests globally.

Within healthcare, the firm is interested in medical devices and diagnostics whose underlying technology is enabled by advanced materials or advanced material process innovations. The firm has a particular interest in 3D bioprinting, diagnostics and genomics/proteomics R&D applications. The firm does not make investments in pharmaceuticals/therapeutics. Past investments have included a manufacturer of semiconductor radiation detectors enabling a new generation of detection and imaging equipment, a company developing a disruptive 3D bioprinting platform, and a company developing functional surfaces with anti-microbial and anti-fouling properties.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.